Published • loading... • Updated
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
Summary by Stemwell Science News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced that its Phase III OptiTROP-Lung06 trial met its primary endpoint, with sac-TMT plus pembrolizumab significantly improving progression-free survival as a first-line treatment for PD-L1-negative advanced non-squamous NSCLC. [Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (PR Newswire)] Press Release
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
